Not in Madrid: Unlike the Tour de France, which finishes with the peloton procession in Paris today, we’re not yet at the ESMO20 finish line and there’s plenty of the data at Congress yet to come.
As you can see, we’re hoping ESMO21 will actually take place in Paris next year, but it’s definitely too early to make travel plans the way COVID-19 infection rates are increasing in Europe.
If we think of cancer drugs as like macarons that come in many versions – which ones do you like at #ESMO20 so far? There are are also subtle gradations in colour and flavour, reflective of a few trial differences to consider.
In this latest post we’re continuing our coverage of highlights from Saturday at ESMO20 with the second part of our commentary and analysis around some of the oral presentations involving numerous solid tumours, excluding breast cancer (see separate highlights of the day post), which caught our attention.
To learn more from our oncology analysis and obtain insights and commentary around data being presented at ESMO20, subscribers can log-in or you can click to gain access to BSB Premium Content.
Looping across different types of analyses can yield intriguing and unexpected results
Not in Chicago – It still feels surreal not to have been to windy city and back for the annual meeting at ASCO this year, such was the ongoing effect of the pandemic in the oncology world.
That said, the virtual meeting has produced some gems this year, including some very important findings many may have missed.
In our latest post meeting report we focus on both biomarkers and clinical findings.
We look at how there are various elements may interplay in unexpected ways, whether signatures from one trial are helpful in another, are there likely to be changes in treatment patterns as a result of data presented and where some emerging early signals might be useful.
One other aspect which crossed my mind was how a deep scientific approach used in one particular cancer might have potential applications in other tumour types with few somatic mutations present such as TNBC, prostate cancer or soft tissue sarcomas.
The results might produce quite different results, yet the process itself might be rather useful to consider…
To learn more from our oncology analysis and get a heads up on insights and commentary emerging from the ASCO meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.
In honour of Armistice / Veteran’s Day 11/11
National Harbor – We’re continuing our SITC 2019 coverage with a look at some intriguing and likely controversial data.
The Best Clinical Data at SITC wasn’t NextCure’s NC318 Siglec–15 (more on that tomorrrow)
Nektar’s pegylated IL–2, bempeg, in combination with nivolumab in frontline metastatic melanoma.
The controversy will no doubt continue to rage with fervent fans and equally intense deniers, but what can we learn from the latest data that was presented by Dr Adi Diab and where are things likely headed?
Included in this latest update are an in-depth thought provoking expert interview with Nektar’s Dr Jonathan ‘JZ’ Zalevsky, plus commentary and analysis on what this all means when we look at the bigger strategic picture.
To learn more from our oncology coverage and get a heads up on our latest insights from the SITC annual meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.
A rare dry spell in Barcelona as the clouds roll in bringing yet more rain
Barcelona – While the weather for the World Congress on Lung Cancer (WCLC) has been largely gloomy with plenty of rainy spells, there’s much good news to report on the clinical front.
After yesterday’s review of the Amgen KRAS inhibitor data in G12C mutation positive patients receiving AMG 510, it’s now time to turn our attention to immunotherapy developments with several important trial readouts and in-depth analyses to discuss.
We will be posting a separate summary of the key highlights on targeted therapy, but first let’s consider what we learned on the immunotherapy front, including some of the science behind it all…
To learn more from our latest oncology conference insights and get a heads up on the details, subscribers can log-in or you can click to gain access to BSB Premium Content.
As we prepare for rolling out some additional expert interviews on a variety of topics together with another mini-series on a tricky target, I wanted to take a moment to explore the Neon Therapeutics data.
Most of the news reports yesterday seemed to be concentrated around a general theme of ’cancer vaccine assist beats immunotherapy drugs alone!’or ‘vaccine boosts Opdivo response in 3 cancers’ … but does the data live up to the breathless hype that ensued? What can we say about the latest clinical update?
As often is the case, the true story around the facts turns out to be much more nuanced and subtle in flavour than the garish headlines might have you believe…
To learn more and get a heads up on our latest oncology insights and thought leader interview, subscribers can log-in or you can click to gain access to BSB Premium Content.
The annual ASCO-SITC meeting (#ImmunoOnc19) was held in San Francisco this year and has come a long way from the inaugural event we attended in Orlando.
Finding the signals amongst the noise
In the original 2017 event, I vividly recall as stirring presentation from Dr Limo Chen on targeting CD38 in solid tumours, last year we wrote an update on GU cancers including the STING pathway.
What’s in store from San Francisco and how do we go about finding key signals from the noise?
Over the next two posts I’m going to focus on new findings in various approaches that either look interesting and worth watching, or where there are lessons that can be learned for future developments.
This time around, some of the highlights surprised even me…
To learn more from our latest conference coverage and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
In the third part of our ASCO GU coverage from San Francisco, which includes previews and post-match commentary, it’s time to turn our attention to renal cancer. This isn’t one disease, but a broad tumour type with multiple subtypes, some based on histology, with perhaps others to emerge down the road as we learn more about the disease and immune profiling.
There’s quite a bit to discuss this year, some of it quite complex and nuanced.
In the old days, much of the focus was on sequencing single agent TKIs in clear cell carcinoma, now it’s getting much more complex as scientists and researchers figure out combinations and regimen approaches, never mind what to do with the various histologies.
We walk readers through the latest information as we await the data presentations coming out tomorrow…
To learn more from our latest cancer conference coverage and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
Genito-urinary (GU) cancers are a diverse population of tumour types that run the gamut from prostate, bladder, penile, and renal cell carcinomas in the main, along with a variety of rare cancers thrown into the mix.
While much attention has tended to be focused on advanced and metastatic disease, for obvious reasons, there are plenty of new developments emerging in earlier stage disease.
This year things are looking up on several fronts, which is a great time to take a look at what to watch out for in GU malignancies…
To learn more from our latest assessment and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
At one point not too distant in the past, all the big news seemed to flow out of advanced prostate cancer with abiraterone and enzalutamide vying for attention, followed by occasional news on ARN–509, ODM–201, galeterone (remember that one from Tokai with all the AR-V7 kerfuffle?), radium Ra–223 dichloride, cabazitaxel, denosumab, ipilumumab, PROSTVAC, brachyury, and a few others. Predictably, not all were successful, and the count is still out on some.
In our latest conference coverage, we take a look at what we can learn from riding the prostate cancer train at ASCO GU ahead of the presentations in San Francisco tomorrow.
We will be updating this review as more data become available with the presentations, so do grab a cup of joe and settle down for some interesting reading ahead of time… this should get you all up to speed on the journey there!
To learn more from our latest conference and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
Hitching a ride on the Powell and Mason tram
Gastrointestinal (GI) cancers comprise quite a wide variety of different tumour types, including those of the oesophagus and stomach, pancreas, small bowel and hepatobiliary tract, as well as the colon, rectum and anus.
With the possible exception of oesophagus and gastric/stomach cancers, this bunch of tumour types are generally colld rather than hot tumours for various reasons.
Aside from some recent forays by immune checkpoint blockade in gastric cancer, this field hasn’t had a lot of startling new developments to get excited about of late.
Are things finally changing?
To learn more and get a heads up on our latest conference coverage, subscribers can log-in or you can click to gain access to BSB Premium Content.